DEVELOPMENT OF A FORMULATION-AGNOSTIC AUTOINJECTOR PLATFORM

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

W6QK ACC-APG

Contract Value

Not provided

Codes & Classification
Solicitation Number

W911SR-26-PLATFORM

NAICS

339112 - Surgical and Medical Instrument Manufacturing

Classification Code

6515

Additional Details
Set Aside

NONE

Place of Performance

Gunpowder, Maryland, UNITED STATES

SourceSAM
Documents2
The Department of Defense, through the Department of the Army and its contracting office W6QK ACC-APG, has issued a Sources Sought notice seeking information and design concepts for the development of a Formulation-Agnostic Autoinjector Platform. This initiative is managed by the Capability Program Executive for Chemical, Biological, Radiological and Nuclear Defense (CPE CBRND), specifically under the Joint Project Manager for CBRN Medical (JPM CBRN Medical). The notice is intended for market research and planning purposes, and does not constitute a solicitation or commit the government to a particular acquisition strategy. The primary objective of this effort is to identify or develop a modular, ruggedized, and highly reliable autoinjector device capable of delivering a range of pharmaceutical formulations. The envisioned platform must accommodate single-chamber liquid, dual-chamber liquid-liquid, and dual-chamber solid-liquid (reconstitution) formulations, making it adaptable to a variety of medical needs in both military and commercial contexts. Key technical requirements include: - **Reliability:** The autoinjector must be designed to meet or exceed an FDA-validated reliability threshold of 99.999% throughout its product lifecycle. - **Flexibility:** The device should be capable of delivering volumes from 0.4 mL to 2.0 mL as a minimum requirement, with an objective capability of up to 5.0 mL. It must handle varying fluid viscosities without necessitating changes to the primary assembly line. - **Ruggedization:** The platform must meet or be capable of being ruggedized to MIL-STD-810H standards, ensuring effective intramuscular delivery even when used through Mission Oriented Protective Posture (MOPP) gear and Army Combat Uniforms (ACU). - **Target Compounds:** Initial candidate compounds for delivery include Atropine, Pralidoxime Chloride (2-PAM), Midazolam, and Naloxone. - **Commercialization:** The government is seeking platform designs that demonstrate clear dual-use pathways, supporting sustainable commercial market viability beyond military procurement. The procurement is classified under NAICS code 339112 (Surgical and Medical Instrument Manufacturing), with product service code 6515. There are no set-aside requirements for this opportunity, making it open to all qualified respondents. The place of performance is Gunpowder, Maryland, United States. Interested parties are encouraged to review the notice and respond by August 7, 2026. The primary point of contact for this opportunity is Imani Daiyaan ([email protected], 520-852-1906), with Alex M. Schupp ([email protected]) as the secondary contact. Additional information, including attachments, can be accessed via the SAM.gov opportunity page at https://sam.gov/opp/b4dd641bf6cb4a6dbb1d132a8f881991/view. Contractors with expertise in medical device design, manufacturing, and commercialization—particularly those with experience in ruggedized, high-reliability autoinjector platforms—are encouraged to evaluate this opportunity for alignment with their capabilities and submit relevant information as requested in the notice.